Edition:
United Kingdom

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

16.27USD
25 Mar 2019
Change (% chg)

$0.11 (+0.68%)
Prev Close
$16.16
Open
$16.11
Day's High
$16.42
Day's Low
$15.79
Volume
188,195
Avg. Vol
248,119
52-wk High
$32.95
52-wk Low
$11.05

About

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that... (more)

Overall

Beta: --
Market Cap(Mil.): $1,116.97
Shares Outstanding(Mil.): 36.11
Dividend: --
Yield (%): --

Financials

  NTLA.OQ Industry Sector
P/E (TTM): -- 69.32 32.54
EPS (TTM): -1.33 -- --
ROI: -17.54 8.89 13.82
ROE: -22.51 10.02 15.24

Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

01 Mar 2019

Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

01 Mar 2019

CORRECTED-Intellia CEO not involved in Starboard's Bristol-Myers board challenge

NEW YORK, Feb 28 Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday.

01 Mar 2019

Earnings vs. Estimates